These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2571616)

  • 61. [Pressure and metabolic effects of terazosin in essential hypertension].
    Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
    Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antihypertensive therapy: taking lipids into consideration.
    Grimm RH
    Am Heart J; 1991 Sep; 122(3 Pt 2):910-8. PubMed ID: 1678922
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Implications of doxazosin therapy on risk of coronary heart disease.
    Hansson L
    Am Heart J; 1988 Dec; 116(6 Pt 2):1832-7. PubMed ID: 2904759
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
    Kirby RS
    Br J Urol; 1998 Sep; 82(3):373-9. PubMed ID: 9772873
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The mechanism of the action of Minipress. Examinations in hypertension.
    Török E; Bíró V; Podmaniczky M
    Ther Hung; 1989; 37(2):90-8. PubMed ID: 2573964
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
    Nash DT; Schonfeld G; Reeves RL; Black H; Weidler DJ
    Am J Cardiol; 1987 May; 59(14):87G-90G. PubMed ID: 2884859
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
    Cohen JD
    Am Heart J; 1991 Sep; 122(3 Pt 2):919-25. PubMed ID: 1678923
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
    Nechwatal W; Berger J; Blumrich W; Bouzo H; Brandl K; Braun S; Laukaitis A; Müller G; Ryba W; Schreiegg J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1806-14. PubMed ID: 2904755
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
    Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
    Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
    van den Hogen AL
    Am Heart J; 1988 Dec; 116(6 Pt 2):1757-62. PubMed ID: 2904746
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
    Somberg JC; Achari R; Laddu AR
    Am Heart J; 1991 Sep; 122(3 Pt 2):901-5. PubMed ID: 1678920
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
    Englert RG; Mauersberger H
    Am Heart J; 1988 Dec; 116(6 Pt 2):1826-32. PubMed ID: 2904758
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mechanism of alpha blockade for blood pressure control.
    Davey M
    Am J Cardiol; 1987 May; 59(14):18G-28G. PubMed ID: 2884849
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
    Davey MJ
    Am J Med; 1989 Aug; 87(2A):36S-44S. PubMed ID: 2569823
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
    Lytle TB; Coles SJ; Waite MA
    J Clin Pharm Ther; 1991 Aug; 16(4):263-73. PubMed ID: 1682328
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A multicenter study of doxazosin in the treatment of severe essential hypertension.
    Soltero I; Guevara J; Silva H; Velasco M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1767-71. PubMed ID: 2904748
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The effect of terazosin and nitrendipine on blood insulin, glucose and lipid in SHR rats].
    Wang W
    Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Aug; 21(4):234-5. PubMed ID: 7910793
    [No Abstract]   [Full Text] [Related]  

  • 80. Trends in alpha-blocker treatment of patients with benign prostatic hyperplasia and hypertension: dosing regimens and cost comparisons.
    Raymond JL; Smith CS
    Clin Ther; 1997; 19(4):821-9. PubMed ID: 9377624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.